🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 45 of 116

  1. Dupilumab

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  2. Durvalumab

    Syndax Pharmaceuticals

    Unresectable Intrahepatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  3. Durvalumab

    United Therapeutics Europe Ltd

    Stage IB Hepatocellular Carcinoma AJCC v8

    phase 2 mab active

    1 trial

  4. Durvalumab + Oleclumab

    MedImmune

    Stage III Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  5. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial

  6. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial

  7. E7080

    Eisai Co.,

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  8. E7090

    Eisai Co.,

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  9. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai Co.,

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  10. EBV-TCR-T (YT-E001) cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 mab active

    1 trial

  11. EBV-specific T cells (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  12. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  13. EG-70 (phase 1)

    Shanghai Antengene Corporation Limited

    Superficial Bladder Cancer

    phase 2 small molecule active

    1 trial

  14. EGF816, EGF816, LEE011, LEE011

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  15. EGFR-TK Inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nonsmall Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. EIK1003 5mg Tablets, PREDNISONE , ABIRATERONE , EIK1003 20mg Tablets, PACLITAXEL

    Eikon Therapeutics

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  17. EIK1004 20mg Tablets, EIK1004 5mg Tablets

    Eikon Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  18. EIK1004-001 (IMP1707-001)

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  19. EIK1005

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  20. EIK1005 10mg Tablets, EIK1005 50mg Tablets, PEMBROLIZUMAB , EIK1005 200mg Tablets

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  21. ELI-002 7P

    Elicio Therapeutics

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  23. EMB-01

    Shanghai University of Traditional Chinese Medicine

    Neoplasms

    phase 2 small molecule active

    1 trial

  24. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  25. ENFORTUMAB VEDOTIN , mRNA-4157, Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Muscle-invasive Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  26. ENMD-2076

    CASI Pharmaceuticals

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  27. ENMD-2076

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  28. ENMD-2076

    CASI Pharmaceuticals

    Advanced Adult Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  29. EOF5

    Fudan University

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  30. EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  31. EPI-7386, Xtandi - 40 mg soft capsules

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  32. ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  33. EXEMESTANE, ANASTROZOLE, LETROZOLE

    Ningbo Cancer Hospital

    Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse

    phase 2 small molecule active

    1 trial

  34. EXEMESTANE, ANASTROZOLE, LETROZOLE, TAMOXIFEN

    Ningbo Cancer Hospital

    Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.

    phase 2 small molecule active

    1 trial

  35. Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

    The George Institute

    Metastatic pancreatic adenocarcinoma

    phase 2 other active

    1 trial

  36. Elacestrant

    Context Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    2 trials

  37. Elironrasib

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  38. Enasidenib

    Agios Netherlands B.V.

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  39. Enasidenib Mesilate, Enasidenib Mesilate, Ivosidenib, Vidaza 25 mg/ml powder for suspension for injection

    Celgene Europe Limited

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  40. Enasidenib Mesylate

    Jazz Pharmaceuticals Ireland Limited

    Recurrent Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  41. Encorafenib + Binimetinib

    Regeneron UK Limited

    Melanoma BRAF V600E/K Mutated

    phase 2 small molecule active

    1 trial

  42. Encorafenib, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules

    Pfizer Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  43. Endostar

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Neoplasms

    phase 2 small molecule active

    2 trials

  44. Endostar

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  45. Endostatins

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  46. Enfortumab vedotin

    United Therapeutics Europe Ltd

    Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  47. Engineered Mitochondrial Vaccine (IMP3-Mito)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  48. Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CML,Blast Phase

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.